RxDoctor Payments Data

Jennifer Sprague

Physician Assistant · Montgomery, OHNPI 1033628268

Payments from drug & device makers

$5,856in general payments, 2019–2025

Across 270 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$678
  • Bridgebio Pharma, Inc.$606
  • Merck$535
  • Boehringer Ingelheim$494
  • Abbott$483
  • Pfizer$473
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$5469%
  • Food & beverage$5,18689%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,856 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$37,926
Medicare patients
86
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis30$748,108
CamzyosMavacamten29$236,346
EntrestoSacubitril/Valsartan230$233,378
OpsumitMacitentan14$179,908
JardianceEmpagliflozin115$116,318
EliquisApixaban121$110,058
FarxigaDapagliflozin Propanediol99$83,574
VerquvoVericiguat15$24,360
Metoprolol Succinate315$4,537
Torsemide238$2,980
Isosorbide Dinitrate37$2,152
Spironolactone298$1,563
Valsartan57$1,483
Eplerenone23$1,287
Amiodarone Hcl66$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$473$858,166151 claims
E.r. Squibb & Sons, L.L.C.Camzyos$186$236,34629 claims
NovartisEntresto$678$233,378230 claims
Actelion Pharmaceuticals US, Inc.Opsumit$136$179,90814 claims
Boehringer IngelheimJardiance$494$116,318115 claims
AstraZenecaFarxiga$418$83,57499 claims
MerckVerquvo$535$24,36015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Montgomery

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →